Biodexa announces allowance of u.s. patent covering oral rapamycin nanoparticle preparations (“erapa”) and use

February 24, 2025 biodexa announces allowance of u.s. patent covering oral rapamycin nanoparticle preparations (“erapa”) and use biodexa plans to initiate a phase 3 registrational study of erapa in familial adenomatous polyposis (fap) next quarter biodexa pharmaceuticals plc (“biodexa” or the “company”)(nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that the u.s. patent and trademark office allowed has u.s. patent application no. 17/391.495 titled “oral rapamycin nanoparticle preparations and use” which was exclusively licensed to biodexa by rapamycin holdings, inc. d/b/a emtora biosciences, along with other patents, in a transaction which closed in april 2024.
BDRX Ratings Summary
BDRX Quant Ranking